Save on Mirikizumab-MRKZ with Coupons, Discounts & Savings Programs

Mirikizumab-MRKZ is available in the following:

• Intravenous Infusion
• Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial
• Subcutaneous Injection
• Injection: 100 mg/mL solution in a single-dose prefilled pen

Mirikizumab-MRKZ is an interleukin-23 antagonist and is used to treat moderate-to-severe active ulcerative colitis in adults.

Mirikizumab-MRKZ is a condition that happens when your own immune system attacks your gut. This causes inflammation in the lining of the colon. In particular, proteins called interleukin-23 (IL-23) play a key role in causing gut inflammation in ulcerative colitis. This inflammation can lead to symptoms like stomach pain and cramping, bloody stools, and diarrhea. Mirikizumab-MRKZ is a type of medication called an interleukin-23 antagonist. It blocks IL-23 from working. And when IL-23 can’t work like usual, it helps reduce inflammation. This helps lessen symptoms of ulcerative colitis.

Treatment with Mirikizumab-MRKZ has two phases: induction and maintenance.

• Induction phase (until month 2 of treatment): The typical induction dose is 300 mg given as an intravenous (IV) infusion every month for the first 3 doses. These infusions are administered by a healthcare professional at a medical center
• Maintenance phase (month 3 and onwards): The typical maintenance dose is 200 mg (two 100 mg prefilled pens) injected under the skin every month

Mirikizumab-MRKZ is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Mirikizumab-MRKZ:

• Upper respiratory tract infections
• Injection site reaction
• Joint pain

Serious side effects are rare with Mirikizumab-MRKZ. Contact your healthcare provider immediately if you experience any of the following.

• Allergic reaction: swelling of face or throat, trouble breathing, hives, itching
• Severe infection: fever, chills, sweating, weakness, flu-like symptoms, muscle pain or weakness, unexplained weight loss
• Liver injury: unexplained rash, yellowing of skin or eyes, vomiting, abdominal pain

There are no major drug interactions listed for Mirikizumab-MRKZ. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Various FDA-approved generic manufacturers

It is not known if Mirikizumab-MRKZ can harm an unborn baby. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Mirikizumab-MRKZ during pregnancy. Pregnant women exposed to Mirikizumab-MRKZ and healthcare providers are encouraged to call Eli Lilly and Company at 1-800-Lilly-Rx (1-800-545-5979).

• Omvoh